Novavax Current Deferred Revenue Over Time
| NVAX Stock | USD 8.62 0.13 1.49% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Novavax Performance and Novavax Correlation. Novavax |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novavax. If investors know Novavax will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novavax listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.709 | Earnings Share (2.18) | Revenue Per Share 6.186 | Quarterly Revenue Growth (0.55) | Return On Assets (0.11) |
The market value of Novavax is measured differently than its book value, which is the value of Novavax that is recorded on the company's balance sheet. Investors also form their own opinion of Novavax's value that differs from its market value or its book value, called intrinsic value, which is Novavax's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novavax's market value can be influenced by many factors that don't directly affect Novavax's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novavax's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novavax is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novavax's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Current Deferred Revenue Analysis
Compare Novavax and related stocks such as Moderna, Inovio Pharmaceuticals, and BioNTech SE Current Deferred Revenue Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MRNA | 107.7 M | 107.7 M | 107.7 M | 107.7 M | 107.7 M | 107.7 M | 107.7 M | 96.7 M | 109.1 M | 63.3 M | 3.9 B | 6.3 B | 2 B | 568 M | 539.6 M |
| INO | 50 K | 468 K | 741.9 K | 2 M | 3.6 M | 14 M | 15.2 M | 1.3 M | 257.2 K | 124.1 K | 46.6 K | 21.6 K | 1 M | 1.2 M | 2.1 M |
| BNTX | 33.5 M | 33.5 M | 33.5 M | 33.5 M | 33.5 M | 33.5 M | 33.5 M | 77.3 M | 66 M | 93.6 M | 391.5 M | 189.1 M | 77.1 M | 353.3 M | 371 M |
| VXRT | 17.5 M | 2.5 M | 300 K | 300 K | 5.9 M | 5.9 M | 3.6 M | 2.9 M | 1.5 M | 4.6 M | 4.2 M | 5.1 M | 2 M | (1.1 M) | (1 M) |
| AZN | (3.2 B) | (6.8 B) | (6.5 B) | (7.9 B) | (8.4 B) | (8.2 B) | (7.5 B) | (8 B) | (11.1 B) | 28 M | 1.6 B | 1 B | 181 M | 149 M | 156.4 M |
Novavax and related stocks such as Moderna, Inovio Pharmaceuticals, and BioNTech SE Current Deferred Revenue description
Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.My Equities
My Current Equities and Potential Positions
| Novavax | NVAX |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Maryland; U.S.A |
| Exchange | NASDAQ Exchange |
USD 8.62
Additional Tools for Novavax Stock Analysis
When running Novavax's price analysis, check to measure Novavax's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novavax is operating at the current time. Most of Novavax's value examination focuses on studying past and present price action to predict the probability of Novavax's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novavax's price. Additionally, you may evaluate how the addition of Novavax to your portfolios can decrease your overall portfolio volatility.